Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, while Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, accounting for 0.58% of the total turnover of the day. The average transaction price was 255 yuan, which was 4.51% lower than the market closing price of 267.03 yuan, of which the highest transaction price was 267.03 yuan and the lowest transaction price was 218.97 yuan.Jinghe Jicheng: Shareholder Lijing Venture Capital intends to transfer 1.50% shares of the company by inquiry, and Jinghe Jicheng announced that shareholder Lijing Venture Capital intends to transfer 30.092 million shares of the company by inquiry transfer, accounting for 1.50% of the company's total share capital.Huitai Medical: Using raised funds and self-owned funds to increase capital of 700 million yuan to wholly-owned subsidiaries. Huitai Medical announced that the company held the 20th meeting of the second board of directors and the 17th meeting of the second board of supervisors on December 12, 2024, and reviewed and approved the Proposal on Using raised funds and self-owned funds to increase capital to wholly-owned subsidiaries. The company agreed to increase its capital by 700 million yuan to Shanghai Hongtong Industrial Co., Ltd., a wholly-owned subsidiary, of which 438 million yuan of interest-bearing loans provided to Shanghai Hongtong with raised funds were converted into capital increase, and 262 million yuan was increased with its own funds. After the capital increase is completed, the registered capital of Shanghai Hongtong will increase from RMB 18,489,300 to RMB 26,548,200, and it will remain a wholly-owned subsidiary of the company.
Huabei Pharmaceutical Co., Ltd.: Four kinds of drugs under the company are planned to be selected for national centralized drug procurement. Huabei Pharmaceutical announced that the company and its subsidiary Xiantai Company participated in the tenth batch of national centralized drug procurement, and all four varieties are planned to be selected, including penicillin sodium for injection, piperacillin sodium for injection, ampicillin sodium for injection and sulbactam sodium for injection. The price of the drug to be selected this time has decreased compared with the original sales price. In 2023, the sales income of penicillin sodium for injection was 129 million yuan, accounting for 1.28% of the annual operating income. If the bid is confirmed and the purchase and sale contract is signed, the company will fully guarantee the supply according to the demand of the selected area, and promote the increment of related products in the selected area and the development of the off-standard market. Huangshan Capsule: It is planned to distribute a cash dividend of 0.27 yuan for every 10 shares. Huangshan Capsule announced that the company held the board of directors and the board of supervisors on December 13, 2024, and reviewed and approved the profit distribution plan for the first three quarters of 2024. According to the plan, the company plans to distribute a cash dividend of RMB27 to all shareholders for every 10 shares based on the existing total share capital of 299 million shares, with a total cash dividend of RMB8,075,700. This profit distribution will not send bonus shares, and capital reserve will not be converted into share capital.
Xinxiangwei: Shareholder Xinyu Yijiade intends to reduce its shareholding by no more than 1%. Xinxiangwei announced that as of the disclosure date, Shareholder Xinyu Yijiade holds 20,175,800 shares of the company, accounting for 4.39% of the company's total share capital. Xinyu Yijiade plans to reduce the number of shares of the company by no more than 4,595,300 shares through centralized bidding or block trading of Shanghai Stock Exchange within 90 days after 15 trading days from the date of announcement, and the proportion of reduced shares in the company's total share capital is no more than 1%.Spot gold fell below $2,660 per ounce, down 0.77% in the day.Zhuhai Guanyu: It has been notified by domestic car companies. Zhuhai Guanyu announced that the company has recently been notified by a domestic car company to select the company as its designated supplier to develop and supply low-voltage lithium batteries for 12V cars.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14